ClinicalTrials.gg
CompletedNCT03366272NIVEAUUpdated Jan 28, 2025

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

A Phase 2/3 interventional study of Nivolumab and Rituximab in Lymphoma, Non-Hodgkin, sponsored by Universität des Saarlandes. Completed at 77 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Universität des Saarlandes · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
348
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 12 studies testing nivolumab in Lymphoma, Non-Hodgkin — 3 open to participants now, 5 under way, none of them phase 3. Nivolumab · Lymphoma, Non-Hodgkin.

Enrollment
3rd of 12
348 · median 109
Started
2017
the only one that year
Phase 2/3
Only one
of the 12
Registered
7th of 12
by date
Lead sponsor
1 of 12
Universität des Saarlandes

Among the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin, this one is the 3rd largest by enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 7th registered.

Lymphoma, Non-Hodgkin

2,288 studies on the registry are indexed under Lymphoma, Non-Hodgkin; 283 are open to participants now.

Browse Lymphoma, Non-Hodgkin studies →

Open to participants now

3 of the 12 studies testing nivolumab in Lymphoma, Non-Hodgkin are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 242 Lymphoma, Non-Hodgkin studies recruiting now, 142 (59%) set no upper age limit and 77 (32%) stop at 75 or younger; 68 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing nivolumab in Lymphoma, Non-Hodgkin, or all of them as a file.
02

Study summary

This study evaluates the addition of nivolumab to gemcitabine, oxaliplatin plus rituximab in case of B-cell lymphoma

Read the detailed description

International, multicentre, randomised, open-label, treatment optimisation study, preceded by safety run-in phases conducted for B-cell and T-cell lymphoma separately.

03

Conditions studied

  • Lymphoma, Non-Hodgkin
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients with first relapse or progression of an aggressive Non-Hodgkin's lymphoma
  • all patient >65 years of age or > 18 years if not eligible for neither autologous nor stem cell transplantation
  • all patient >65 years of age or older than 18 years if HCT-CI score > 2 or patients who underwent prior autologous stem cell transplantation and are not eligible for allogeneic stem cell Transplantation
  • All risk groups (IPI 0 to 5)
  • Diagnosis of aggressive Non-Hodgkin's lymphoma, based on an excisional of a lymph node or on an appropriate sample of a lymph node or of an extranodal involvement at initial diagnosis or relapse or Progression. The entities treated in the study will be based on the WHO 2017 classification.
  • 0 - 2
  • only one prior chemotherapy regimen including an anthracycline. The last cytotoxic drug must be given at least four weeks before entering the study. Rituximab must be part of the regimen in case of B-cell lymphoma (except for primary CD20- negative lymphoma). Patients may have received prior radiation therapy as part of their first-line therapy
  • Men who are sexually active with women of (WOCBP) must not father a child during and up to 6 months after GemOx and up to 12 months after Rituximab and/or Nivolumab. They are advised to do cryoconservation of sperm prior to treatment.
  • Written of the patient
  • Patient must be covered by social security system

Exclusion criteria

Exclusion Criteria:

  • Already initiated lymphoma therapy after first relapse or progression
  • Serious accompanying disorder or impaired organ function
  • WBC \< 2.5 G/l, Neutrophils \< 2 G/l, \< 100 G/l
  • Prolongation of > 450 ms, demonstrated in one (done as triplicate). This does not apply for patients with a block of the right and/or left bundle branch.
  • Family history for Long QT-Syndrome
  • active, known or suspected disease
  • no requirement for doses of systemic
  • Chronic active or C
  • -infection
  • Patients with a severe immunodeficiency
  • Previous therapy with Nivolumab,Gemcitabine or Oxaliplatin
  • Patients with a "currently active" second other than non-melanoma skin cancer
  • CNS involvement of lymphoma
  • Persistent neuropathy grade >2
  • Pregnancy or breast-feeding women
  • Women of
  • Active serious infections not controlled by oral and/or intravenous antibiotics or anti-fungal medication
  • Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities
  • Lymphomas other than those listed in the inclusion criteria notably indolent lymphoma, Mantle cell lymphoma, Burkitt lymphoma, adult T-cell leukemia/lymphoma.
  • Persons not able to understand the impact, nature, risks and consequences of the trial (including language barrier)
  • Persons not agreeing to the transmission of their pseudonymous data
  • Persons depending on sponsor or investigator
  • Persons from highly protected Groups
  • Allergies and Adverse Drug Reaction History to study drug components
  • Participation in another clinical trial with drug intervention within 4 weeks prior to start of the first cycle and during the study. However, participation in a clinical trial of firstline therapy of lymphoma is allowed.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
348 participants (actual)

Study arms

  • Active comparator
    (R)-GemOx

    eight cycles of (R)-GemOx (Gemcitabine 1000 mg/m2, d1, Oxaliplatin 100 mg/m2, d1, Rituximab 375 mg/m2 in case of B-cell lymphoma disease, repeated every 2 wks)

    Drug: Rituximab · Drug: Gemcitabine · Device: Oxaliplatin

  • Experimental
    Nivo-(R)-GemOx

    eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first

    Drug: Nivolumab · Drug: Rituximab · Drug: Gemcitabine · Device: Oxaliplatin

Interventions

  • eight cycles of nivolumab (240 mg flatdose) plus (R)-GemOx in 2-wk intervals followed by additional 9 infusions of Nivolumab (480 mg flatdose) in 4-wk intervals as consolidation or up to progression or unacceptable toxicity, whatever occurs first

  • eight cycles of R-GemOx in 2-wk intervals

  • eight cycles of (R)-GemOx in 2-wk intervals

  • DeviceOxaliplatin

    eight cycles of (R)-GemOx in 2-wk intervals

06

What researchers measure

Primary outcomes

  1. PFS

    Progression free survival

    Time frame: 1 year

Secondary outcomes

  1. CR rate

    complete response rate

    Time frame: 4-6 weeks after cycle 8 (each cycle is 14 days)

  2. PR rate

    partial response rate

    Time frame: 4-6 weeks after cycle 8 (each cycle is 14 days)

  3. ORR rate

    overall response rate

    Time frame: 4-6 weeks after cycle 8 (each cycle is 14 days)

  4. Duration of response

    Duration of response

    Time frame: up to 2 years after inclusion of last patient

  5. Primary Progression rate

    Rate of Primary progression

    Time frame: up to 2 years after inclusion of last patient

  6. Treatment related deaths rate

    Rate of Treatment related deaths

    Time frame: up to 2 years after inclusion of last patient

  7. Relapse rate

    Rate of relapses

    Time frame: up to 2 years after inclusion of last patient

  8. EFS

    Event free survival

    Time frame: up to 2 years after inclusion of last patient

  9. OS

    Overall survival

    Time frame: up to 2 years after inclusion of last patient

  10. Toxicities: rates and grades of adverse events

    Toxicity: Rates and grades of toxicities will be determined according to CTC-v4.03

    Time frame: up to 2 years after inclusion of last patient

  11. Protocol adherence according to number of given chemotherapy cycles

    Protocol adherence will be determined according to number of chemotherapy cycles

    Time frame: up to 2 years after inclusion of last patient

  12. Protocol adherence according to duration of given chemotherapy cycles

    Protocol adherence will be determined according to duration of chemotherapy cycles

    Time frame: up to 2 years after inclusion of last patient

  13. Protocol adherence according to cumulative dose of immunochemotherapy given

    Protocol adherence will be determined according to cumulative dose of immunochemotherapy given

    Time frame: up to 2 years after inclusion of last patient

  14. Protocol adherence according to relative dose of immunochemotherapy given

    Protocol adherence will be determined according to relative dose of immunochemotherapy given

    Time frame: up to 2 years after inclusion of last patient

  15. QoL

    Quality of Life (QoL) will be assessed by the EQ-5D-5L questionnaire

    Time frame: up to 1 year after inclusion of last patient

  16. Biological Parameters according to PD-L1 expression alterations

    Outcome assessment of response according to PD-L1 expression alterations

    Time frame: up to 2 years after inclusion of last patient

  17. Biological Parameters according to PD-1 expression

    Outcome assessment of response according to PD-1 expression

    Time frame: up to 2 years after inclusion of last patient

  18. Biological Parameters according to cell of origin

    Outcome assessment of response according to cell of origin

    Time frame: up to 2 years after inclusion of last patient

  19. Biological Parameters according to 9p24.1 alterations

    Outcome assessment of response according to 9p24.1 alterations

    Time frame: up to 2 years after inclusion of last patient

07

Study locations

77 sites
  • Landeskrankenhaus Feldkirch
    Feldkirch, Austria
  • Innsbruck University Hospital
    Innsbruck, Austria
  • Kepler Universitätsklinikum GmbH- Med. Campus III
    Linz, Austria
  • Ordensklinikum Linz - Elisabethinen
    Linz, Austria
  • Ordensklinikum Linz - Krankenhaus der Barmherzigen Schwestern Linz
    Linz, Austria
  • Paracelsus Medical University Salzburg
    Salzburg, Austria
  • Klinikum Wels-Grieskirchen GmbH
    Wels, Austria
  • Universitätsklinik für Innere Medizin I, AKH Wien
    Wien, Austria
  • INSTITUT JULES BORDET -Hematology
    Brüssel, Belgium
  • UNIVERSITE CATHOLIQUE DE LOUVAIN SAINT-LUC - Hematology
    Brüssel, Belgium
  • UNIVERSITAIR ZIEKENHUIS GENT - Hematology
    Gent, Belgium
  • CHU DE LIEGE - Hematology
    Liège, Belgium
  • UNIVERSITE CATHOLIQUE DE LOUVAIN MONT GODINNE - Hematology
    Yvoir, Belgium
  • CHU Côte de Nacre - Service Hématologie Clinique
    Caen, France
  • Hôpital Henri Mondor - Unité "Hémopathies Lymphoïdes" - HDJ 11è
    Créteil Cedex, France
  • CHU Dijon - Hôpital d'Enfants - Hématologie Clinique
    Dijon, France
  • CHU de Grenoble - Hôpital Albert Michallon - Hématologie Clinique
    Grenoble, France
  • CH Départemental Vendée - Onco-Hématologie
    La Roche-sur-Yon, France
  • CHRU de Lille - Hôpital Claude Hurriez
    Lille, France
  • CHU de Montpellier - Hématologie Clinique
    Montpellier, France
  • CHU de Nantes - Hôtel Dieu - Hématologie
    Nantes, France
  • Hôpital Saint Louis - Onco-Hématologie
    Paris cedex 20, France
  • Hôpital Necker - Hématologie Clinique
    Paris, France
  • CHU de Bordeaux - Hôpital Haut Lévêque - Centre François Magendie
    Pessac, France
  • CHU Lyon Sud - Hématologie
    Pierre-Bénite, France
  • Hôpital Pontchaillou - Hématologie
    Rennes, France
  • Centre Henri Becquerel - Hématologie
    Rouen, France
  • Institut de Cancèrologie Lucien Neuwirth
    Saint-Priest-en-Jarez, 42271, France
  • Hôpitaux Universitaires de Strasbourg - Hôpital de Hautepierre
    Strasbourg, France
  • IUCT Oncopole - Hématologie
    Toulouse, France
  • CHU Nancy - Hôpital de Brabois - Service d'Hématologie et Médecine Interne
    Vandoeuvre-les-Nancy, France
  • Sozialstiftung Bamberg
    Bamberg, Germany
  • Charité - Universitätsklinikum Berlin, Med. Klinik m. S. Hämatologie
    Berlin, Germany
  • Vivantes Klinikum am Urban, Klinik für Innere, Hämatologie und Onkologie
    Berlin, Germany
  • Klinikum Chemnitz, Innere Medizin III
    Chemnitz, Germany
  • BAG Freiberg-Richter, Jacobasch, Wolf, Illmer
    Dresden, Germany
  • Gemeinschaftspraxis Dres. Mohm, Prange-Krex
    Dresden, Germany
  • St. Antonius-Hospital Eschweiler, Klinik für Hämatologie
    Eschweiler, Germany
  • Universitätsklinikum Essen, Klinik für Hämatologie
    Essen, Germany
  • Universitätsmedizin Göttingen, Klinik für Hämatologie
    Göttingen, Germany
  • Universitätsklinikum Haale (Saale), Klinik für Innere Medizin IV
    Haale, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, Germany
  • Universitätsklinikum des Saarlandes, Innere Med. I
    Homburg, Germany
  • Westpfalz-Klinikum, Klinik für Innere Medizin I
    Kaiserslautern, Germany
  • St. Vincentius Kliniken Karlsruhe, Med. Klinik Abt. 2
    Karlsruhe, Germany
  • Uni Gießen und Marburg, Klinik für Hämatologie
    Marburg, Germany
  • Stauferklinikum Schwäbisch Gmünd, Zentrum für Innere Medizin
    Mutlangen, Germany
  • Klinikum der Universität München, Med. Klinik und Poliklinik III
    München, Germany
  • Universitätsklinikum Münster
    Münster, Germany
  • Brüderkrankenhaus St. Josef Paderborn
    Paderborn, Germany
  • Universitätsklinikum Regensburg, Klinik für Innere Medizin III
    Regensburg, Germany
  • Universitätsmedizin Rostock, Klinik für Hämatologie
    Rostock, Germany
  • Klinikum Stuttgart, Klinik für Hämatologie
    Stuttgart, Germany
  • Klinikum Mutterhaus der Borromäerinnen, Med. Abteilung I
    Trier, Germany
  • Krankenhaus der Barmherzigen Brüder, I. Med. Abteilung
    Trier, Germany
  • Universitätsklinikum Tübingen, Innere Medizin II
    Tübingen, Germany
  • Uniklinikum Ulm, Klinik für Innere Medizin III
    Ulm, Germany
  • Schwarzwald-Baar Klinikum, Innere Medizin II
    Villingen-Schwenningen, Germany
  • The Chaim Sheba Medical Center - Division of Hematology and Bone-Marrow Transplantation
    Ramat Gan, Israel
  • MC Alkmaar
    Alkmaar, Netherlands
  • AMC Academisch Medisch Centrum
    Amsterdam, Netherlands
  • VUMC
    Amsterdam, Netherlands
  • Reinier de Graaf Gasthuis
    Delft, Netherlands
  • Maxima Medisch Centrum
    Eindhoven, Netherlands
  • MC Leeuwarden Zuid
    Leeuwarden, Netherlands
  • Antonius Ziekenhuis
    Nieuwegein, Netherlands
  • Radboudumc Nijmegen
    Nijmegen, Netherlands
  • Szpital Specjalistyczny w Brozowie
    Brzozów, Poland
  • Oncologic Center
    Bydgoszcz, Poland
  • Uniwersyteckie Centrum Kliniczne
    Gdańsk, Poland
  • Swietorkrzyskie Centrum Oncologii
    Kielce, Poland
  • Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie
    Kraków, Poland
  • Samodzielny Publiczny Szpital Kliniczny Nr. 1
    Lublin, Poland
  • Oncologic Center
    Tomaszów Mazowiecki, Poland
  • Marie Sklodowska-Curie Institute and Oncology
    Warsaw, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, Poland
  • Instituto Português Oncologia - Hematology
    Lisboa, Portugal
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2017 to primary completion in Jan 2025, 85 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2017
First posted
Dec 8, 2017
StartActual
Dec 5, 2017
Primary completionActual
Jan 15, 2025
CompletionActual
Jan 15, 2025
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03366272
Lead sponsor
Universität des Saarlandes
Collaborators
Bristol-Myers Squibb, Lymphoma Study Association, University of Leipzig
Responsible party
Sponsor
First posted
Dec 8, 2017
Start date
Dec 5, 2017
Primary completion
Jan 15, 2025
Completion
Jan 15, 2025
Last update
Jan 28, 2025

Study contacts

Gerhard Held, Prof
principal investigator · Universität des Saarlandes

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nivolumab

Start the discussion